2026-04-21T09:00:56Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/2455-5363.000023 2019-06-06 PTZ.GJIDCR:VOL5

Study of Immunogenicity and Protective Efficacy of Live MDCK-derived Pandemic Influenza Vaccine Elena A Nechaeva Ryzhikov AB Pyankova OG Radaeva IF Pyankov OV Danilchenko NV Agafonov AP Kiseleva LV Larionova NVRudenko LG<p>Background: The threat of pandemic A/H1N1 influenza is still a matter of considerable public concern. Influenza outbreak in 2009 underlined the importance of rapid production of a sufficient vaccine reserve for pandemic and interpandemic periods. One promising way to allay this concern is development of cell culture-derived live attenuated influenza vaccines (LAIV), because this technology makes it possible to produce a considerable amount of vaccine over a short period of time.</p><p>Objectives: The goal of this work was to study the immunogenic and protective properties of the Vector-Flu vaccine in animal models.</p><p>Methods: We have developed Vector-Flu, a live attenuated vaccine against pandemic influenza, based on the cold-adapted reassortant vaccine strain for LAIV, A/17/California/2009/38(H1N1), and produced in certified MDCK cells. The immunogenicity and protective efficacy of Vector-Flu vaccine were studied in ferrets and mice.</p><p>Results: A double immunization with the live MDCK-derived Vector-Flu influenza vaccine induced a high level of neutralizing antibodies in ferret serum both to the pandemic A/Chita/3/2009(H1N1) influenza virus strain, isolated in Russia, and to the pandemic A/California/7/2009(H1N1) strain. Intranasal immunization of mice induced levels of serum antibodies sufficient to protect them when aerosol-challenged with 100 infectious doses of A/Chita/3/2009(H1N1) strain.&nbsp;</p><p>Conclusion: Theoretical estimates of protective antibody levels necessary for protecting humans from the disease caused by pandemic A/H1N1(2009) influenza virus, and the experimental data from animal models (ferrets and mice), suggest that the Vector-Flu vaccine is able to protect humans after a single immunization.</p> Global Journal of Infectious Diseases and Clinical Research - Peertechz Publications 2019-06-06 Research Article https://doi.org/10.17352/2455-5363.000023 en Copyright © Elena A Nechaeva et al.